sarcoma

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.

PF-562271 hydrochloride (PF-562271 HCl) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).

PMEDAP is a potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and mortality, as well as a human immunodeficiency virus (HIV) replication inhibitor with anti-murine cytomegalovirus (MCMV) activity.

Seclidemstat (SP-2577) is an effective LSD1 inhibitor, with a mean IC50 of 127 nM.

Laminin β2 (Engelbreth-Holm-Swarm murine sarcoma basement membrane) is a crucial structural component in animal tissues, forming part of the framework that supports tissue architecture. It interacts with type IV collagen through entactin and basement membrane proteoglycans and associates with cell membranes via integrin receptors, dystroglycan complexes, and Lutheran blood group glycoproteins. Additionally, it contains functional domains that facilitate collagen binding, cell adhesion, heparin interactions, and promote neurite outgrowth.

Osteosarcoma-IN-D14 is an inhibitor of migration and invasion of osteosarcoma cells mediated by p53, regulating EMT-related genes.

Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.

Silver chloride can be used as a buffer in electrodes or spectroscopic analysis. Silver chloride exhibits inhibitory activity against various bacteria and demonstrates antitumour activity against Ewing sarcoma when formulated as nanoparticles (AgCl-NPs).

BK60106 is a selective inhibitor of the transmembrane protein CD99, which causes cell death in Ewing Sarcoma cells by directly binding to the extracellular structural domain of CD99.

Dacarbazine citrate is an alkylating agent used to treat cancers of the lymphatic system and malignant melanoma (a type of skin cancer) in patients with certain conditions: islet cell carcinoma (part of the pancreas) Soft tissue sarcoma (cancer of muscles

Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research. Trabectedin inhibits cell growth of MX-1, MCF7 and MCF7/DXR cells with IC50 values of 0.1 nM, 1.5 nM and 3.7 nM, respectively.

SXT1596 is a novel SS18-SSX/TLE1 interaction inhibitor. SXT1596 reduces cell viability and reactivates EGR1 expression in synovial sarcoma.

NSC635437 acts as an inhibitor of the EWS-FLI1 oncoprotein in Ewing's sarcoma.

Olomorasibum is an inhibitor of Kirsten rat sarcoma viral oncogene homolog (KRAS) and belongs to the category of antitumor compounds.

Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.

EB-TCIP (BAK-04-212) is a bivalent molecule composed of AP1867 and BI-3812. It facilitates the reversible formation of a ternary complex between FKBPF36V and BCL6BTB, thereby recruiting FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, rapidly inducing expression of BCL6 target genes such as SOCS2 and CXCL11. EWS/FLI1 is a fusion transcription factor found in Ewing sarcoma. EB-TCIP is applicable for studying transcriptional dysregulation in cancer.

Reveromycin C is a polyketide compound originally isolated from Streptomyces, exhibiting antifungal activity against Candida albicans with a MIC of 2.0 μg/mL at pH 3 and >500 μg/mL at pH 7.4. It inhibits EGF-induced mitogenic activity in Balb/MK mouse epidermal cell lines. Additionally, it reverses the morphology of sarcoma virus-transformed NRK rat kidney cells (EC50 = 1.58 μg/mL) and inhibits the proliferation of KB cells and K562 human chronic myelogenous leukemia cells (IC50 = 2.0 μg/mL for both).

Anticanceragent 187 (Compound 4) is an anticancer agent that targets sarcoma cells in tumor-bearing mouse models. It exhibits cytotoxicity against HepG2, Caco2, and MCF-7 cell lines.

RETRA is an agent of anticancer that acts by exerting anticancer activity in Ewing's sarcoma cells independent of their TP53 status.

FR 900490 is an immunoactive substance produced by a fungus Discosia sp. F-11809. In vitro FR-900490 restores the colony forming units in culture (cfu-c) in bone marrow cells, which were suppressed by immunosuppressive factor obtained from the serum of sa

DC 86M is an antitumor antibiotic isolated from the culture broth of Streptomyces luteogriseus DO-86. DC 86M is active against Gram-positive and Gram-negative bacteria and experimental murine sarcoma 180.

Potent BRD9 degrader. Selectively binds BRD9 and elicits near complete degradation of BRD9 at nanomolar concentrations. Inhibits growth of synovial sarcoma cells in vitro and tumor progression in a synovial sarcoma xenograft mouse model.

YW3-56 is an inhibitor of protein arginine deiminase 2 (PAD2) and PAD4 (IC50s = 0.5-1 and 1-5 μM, respectively).1It inhibits the growth of U2OS osteosarcoma cells (IC50= ~2.5 μM) in a p53-dependent mannerviainduction of SESN2 and subsequent inhibition of mTORC1. YW3-56 (10 mg kg) reduces tumor growth in an S-180 murine sarcoma tumor model. It also inhibits tumor growth in the 1883 MDA-MB-231 breast cancer bone metastasis mouse xenograft model.2 1.Wang, Y., Li, P., Wang, S., et al.Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activityThe Journal of Biological Chemisty287(31)25941-25952(2012) 2.Wang, S., Chen, X.A., Hu, J., et al.ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cellsMol. Cancer Ther.14(4)877-888(2015)